Vorasidenib for teens with a grade 2 brain tumor that has an IDH gene change
Original title: Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage study, so the medicine is still being tested and is not regular care.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a medicine called vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary in young people with a slow growing brain tumor.
Who this trial is for. This trial is for people aged 12 to under 18 who have a grade 2 glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary, such as an astrocytoma or an oligodendroglioma, with a change in the IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary or IDH2 gene. It is testing a medicine called vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary, taken in treatment cycles that last 28 days.
Where it stands. The trial has not reported results. It is measuring how safe the medicine is, how well people handle it, and how well it works. It is also looking at growth and development, with long term follow up for about 5 years after treatment starts, or until Tanner Stage V is reached, whichever is later. Taking part can include blood tests, heart tests, scans such as MRI and X-ray, vital sign checks, and physical exams. The answers are not in yet.
What this means, and what it doesn't
What it could mean: If a young person in your family fits this picture, it may be worth asking their care team about this study. The care team can explain what taking part would involve and whether it makes sense for them.
What it doesn't mean: This does not mean vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary is a proven treatment for these tumors. A trial is a test. Being in one is not a guarantee that it will help. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 10, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.